CAJ | 학술논문

目的：研究吡柔比星（THP）膀胱灌注对预防膀胱癌术后发作的临床疗效。方法选取2012年4月～2013年11月期间我院收治的46例膀胱癌患者作为研究对象，所有患者在经尿道膀胱肿瘤电切术后随机分为A、B两组。A、B两组分别为THP和丝裂霉素C（MMC）膀胱灌注，手术后第1周开始，每周1次，共8次，以后每2周1次，共8次，再以后每月1次，共2年。结果86例患者均随访2年以上，A组患者复发率0，B组为21.05%，两者具有统计学差异（P＜0.05）；且A组发生各种不良反应的患者均少于B组，局部不良反应中发生尿频的患者差异显著（P＜0.05），血尿、膀胱疼痛和膀胱炎差异不显著（P＞0.05）；全身不良反应差异显著（P＜0.05）。结论 THP膀胱灌注对预防膀胱癌术后发作具有良好的临床效果，且无严重不良反应，值得在临床上应用。
목적：연구필유비성（THP）방광관주대예방방광암술후발작적림상료효。방법선취2012년4월～2013년11월기간아원수치적46례방광암환자작위연구대상，소유환자재경뇨도방광종류전절술후수궤분위A、B량조。A、B량조분별위THP화사렬매소C（MMC）방광관주，수술후제1주개시，매주1차，공8차，이후매2주1차，공8차，재이후매월1차，공2년。결과86례환자균수방2년이상，A조환자복발솔0，B조위21.05%，량자구유통계학차이（P＜0.05）；차A조발생각충불량반응적환자균소우B조，국부불량반응중발생뇨빈적환자차이현저（P＜0.05），혈뇨、방광동통화방광염차이불현저（P＞0.05）；전신불량반응차이현저（P＜0.05）。결론 THP방광관주대예방방광암술후발작구유량호적림상효과，차무엄중불량반응，치득재림상상응용。
Objective To study the pirarubicin(THP) on the clinical effect of intravesical instillation to prevent bladder cancer postoperative seizure. Methods 46 cases of bladder cancer in our hospital from April 2012 to November 2013 were selected as the object of study, all patients in transurethral resection of bladder tumor were randomly divided into A, B two groups. A, B two groups were respectively THP and mitomycin C(MMC) in bladder perfusion, operation after the first week, 1 times a week for a total of 8 times,later every two weeks a total of 8 times,1 times a month to a total of two years later. Results 46 patients were followed up for more than two years, the A group patients relapse rate was 0, B group 21.05%, both had statistical difference(P < 0.05); and the adverse reactions in A group were less than that in B group, the differences in patients with urinary frequency of local adverse were significant(P<0.05), but hematuria, bladder pain and cystitis were not significant(P>0.05);systemic adverse reactions were significantly different (P<0.05). Conclusion Intravesical instillation of THP has good clinical effect on prevention of bladder cancer postoperative seizure, and no serious adverse reactions, is worthy of clinical application.